Founded in July 2006, Shangdong Huaxi Pharmaceutical Co., Ltd. is a modern private pharmaceutical group co-invested by Beijing Huaxipharm Co., Ltd, it covers 78, 000 square meters with a total invest more than 120 million RMB, specializing in the development, production and marketing of generic and proprietary branded drugs as well as active pharmaceutical ingredients.

Currently, Shangdong Huaxipharm has established API plant conform to GMP, R8D Lab, QC center and modern Storage with Preparation Plant under construction including injections, tablets, capsules, granules lines. Over 20 products have got the clinical study certificate from SFDA.

Huaxipharm Group specializing in developing new drug focuses on neuroscience, endocrine disorders, cancer, infectious diseases, cardiovascular diseases, and inflammation therapeutic area. Long-term extensive cooperation has been maintained with many international enterprises and more than 60 local companies.

with the strength in strong technical support and integration of rich resources, Huaxi HuaxiPharma Group and Shandong HuaxiPharma rising rapidly for specialization and industrialization, continuing to promote innovation in China's medical technology market, pioneering the future of medicine!